The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis

Han Zhu; Yuhsin Vivian Huang; Sean M Wu

doi:10.1016/j.medj.2022.12.005

The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis

Med. 2023 Jan 13;4(1):13-14. doi: 10.1016/j.medj.2022.12.005.

Authors

Han Zhu¹, Yuhsin Vivian Huang², Sean M Wu³

Affiliations

¹ Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA; Stanford University School of Medicine, Stanford, CA, USA.
² Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
³ Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA; Stanford University School of Medicine, Stanford, CA, USA. Electronic address: smwu@stanford.edu.

PMID: 36640753
DOI: 10.1016/j.medj.2022.12.005

Abstract

Immune checkpoint inhibitor (ICI)-mediated myocarditis is a rare but devastating side effect of cancer immunotherapy with up to 40% mortality and long-term cardiac issues such as arrhythmias and heart failure in affected patients.¹ Recently, Axelrod et al.² suggested an auto-antigen-driven mechanism as the immunological basis for this disease.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects
Immunotherapy / adverse effects
Myocarditis* / chemically induced
Myocarditis* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological

Abstract

Publication types

MeSH terms

Substances

Grants and funding